NICE recommends apixaban for stroke prevention in AF

New guidance from NICE recommends the use of apixaban (Eliquis) as an option for preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation.

The licensed dose is 5mg twice daily but this is reduced to 2.5mg twice daily in certain situations | SCIENCE PHOTO LIBRARY
The licensed dose is 5mg twice daily but this is reduced to 2.5mg twice daily in certain situations | SCIENCE PHOTO LIBRARY

Use of apixiban is restricted to patients with one or more risk factors for stroke or systemic embolism, including:

  • prior stroke or transient ischaemic attack
  • age ≥75 years
  • hypertension
  • diabetes mellitus
  • symptomatic heart failure.

Initiation

The decision to start treatment with apixaban should be based on a risk to benefit analysis of the oral factor Xa inhibitor compared with warfarin, dabigatran and rivaroxaban. In patients currently receiving warfarin, the existing level of INR control should be taken into account. 

NICE guidance on apixaban for stroke prevention in AF

Follow MIMS on Twitter


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.